Roche, Exelixis’ Drug Combo Bounces Back with Late-Stage Prostate Cancer Win

Pictured: Roche Diagnostics headquarters in California/iStock, JHVEPhoto The combination of Roche ’s Tecentriq (atezolizumab) and Exelixis ’ Cabometyx (cabozantinib) met one of the primary endpoints in the pivotal Phase III CONTACT-02 trial, significantly improving progression-free survival in patients with metastatic castration-resistant prostate cancer, according to interim data released Monday […]

Click here to view original web page at www.biospace.com